AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03915496 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-04965842 200 mg
Description: PF-04965842 200 mg administered as two tablets to be taken orally once daily for 12 weeks
Study NCT03915496 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-04965842 100 mg
Description: PF-04965842 100 mg administered as two tablets to be taken orally once daily for 12 weeks
Study NCT03915496 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo administered as two tablets to be taken orally once daily for 12 weeks
Study NCT00664391 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lactic acid (Dermacid)
Description: Liquid soup to be applied in the external genital area, in small quantity, with abundantly rinse after use, during 21 days
Study NCT02303301 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Probiotics
Description: Cultures from the oropharynx
Study NCT02303301 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Cultures from the oropharynx
Study NCT03755492 — intervention group
Intervention type: OTHER
Intervention: Absorbent pad for urinary incontinence
Description: 6 month supply provided to patients as needed for urinary incontinence after radical prostatectomy
Study NCT01058109 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: calcium-rich diet
Description: dietary calcium intake of 1500 mg/d
Study NCT01058109 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Calcium rich diet
Description: dietary intake of 1500 mg/d from food
Study NCT03619486 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Low energy shock wave
Description: Probe be transcutaneous applied to the suprapubic bladder region with 2000 shocks, frequency of 3 pulses per second and maximum total energy flow density 0.25 millijoule/mm2 once a week for 4 weeks
Study NCT03619486 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Probe be transcutaneous applied to the suprapubic bladder region with 2000 shocks, frequency of 3 pulses per second but no energy once a week for 4 weeks
Study NCT02513290 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bilastine
Study NCT02513290 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Loratadine
Study NCT02534558 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: miR 29a
Description: Effects of IL-1β, miR-29a precursor or antisense oligonucleotide treatment on the expressions of miR-29a, miR-29b or miR-29c in cell cultures are quantified
Study NCT00169234 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PCV7, Prevnar®
Description: Randomized to receive 0.1mL, 0.5mL, 1.0mL or 2.0mL at the enrollment visit, followed by 0.1mL PPV23 12 months later.
Study NCT00169234 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pneumovax 23
Description: Randomized to receive 0.5mL at the enrollment visit, followed by 0.1mL PPV23 12 months later.
Study NCT01986309 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lidocaine
Description: Bolus 1.5 mg/kg over 5 minutes, then an infusion of 2 mg/kg/h
Study NCT01986309 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline
Description: Sodium Chloride 0.9% infusion
Study NCT01164696 — intervention group
Intervention type: DRUG
Intervention: [90]Y-ibritumomab tiuxetan (Zevalin, BAY86-5128)
Description: Zevalin was administered according to the directives in the approved package leaflet.
Study NCT06608953 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Enhanced external counterpulsation
Description: A device applying external pneumatic cuff pressure to the lower limbs, thighs, and buttock sequentially in the diastolic phase synchronouslty with electrocardiography to assist the cardiac function via diastolic augmentation mechanism.
Study NCT04193085 — intervention group
Intervention type: OTHER
Intervention: Observational
Description: Observational
Study NCT03532854 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Valsartan
Description: Valsartan P.O
Study NCT03532854 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ezetimibe/Rosuvastatin
Description: Ezetimibe/Rosuvastatin P.O
Study NCT03305549 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Conservative dialysis strategy
Description: Participants will receive RRT only when meeting 1 of the following indications (patterned after the AKIKI trial's delayed RRT initiation arm):~* Blood urea nitrogen >112 mg/dL (40 mmol/L)~* Serum potassium concentration >6 mmol/L~* Serum potassium concentration >5.5 mmol/L despite medical treatment (e.g., bicarbonate, glucose-insulin infusion, albuterol, diuretics, sodium polystyrene sulfonate)~* Arterial blood gas pH \<7.15 in a context of pure metabolic acidosis (PaCO2 \<35 mmHg) or in a context of mixed acidosis with PaCO2 50 mmHg despite medical treatment to reverse respiratory acidosis (e.g., naloxone), or in the absence of an available arterial blood gas, serum bicarbonate \<12 mmol/L~* Acute pulmonary edema due to fluid overload, responsible for hypoxemia requiring oxygen flow rate >5 L/min to maintain SpO2 >95% or requiring FiO2 >50% in patients already on invasive or non-invasive mechanical ventilation and despite diuretic therapy
Study NCT03305549 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: TIW dialysis strategy
Description: Thrice-weekly acute intermittent hemodialysis schedule.
Study NCT04741958 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Ultrasound Guided Peripheral Thoracic Tumors
Description: Transthoracic ultrasonography: Transthoracic US was done using machine Hitachi 5500 in the Diagnostic Ultrasound Unit - Chest Department- Kasr El-Aini Hospital.on 60 patients that had radiographic evidence of thoracic mass suspected of malignancy
Study NCT04348149 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Lindera obtusiloba extract
Description: One package of dietary supplement contains one gram of 70% ethanol extracted powder of Lindera obtusiloba and one gram of glucose powder. Participants intake one package per day for 8 weeks.
Study NCT00561002 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 2007-2008 Influenza Virus Vaccine
Description: 0.25 mL, Intramuscular
Study NCT01809145 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: MELISA test
Description: MELISA test for hypersensitivity to metals in sarcoidosis
Study NCT01817699 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High Hb target
Description: 25 to 250 μg of methoxy polyethylene glycol epoetin beta (Mircera®, Chugai pharmaceutical Co. Ltd.) will be administered subcutaneously at 2- to 6-week interval.~Dose and interval will be adjusted according to hemoglobin level and its target.
Study NCT01817699 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: High Hb target
Description: 25 to 250 μg of methoxy polyethylene glycol epoetin beta (Mircera®, Chugai pharmaceutical Co. Ltd.) will be administered subcutaneously at 2- to 6-week interval.~Dose and interval will be adjusted according to hemoglobin level and its target.
Study NCT01798004 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Autologous Hematopoietic Stem Cell Transplantation
Description: Undergo autologous peripheral blood stem cell transplant
Study NCT01798004 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Busulfan
Description: Given IV
Study NCT01798004 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Given IV
Study NCT01798004 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Given IV
Study NCT01798004 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin Hydrochloride
Description: Given IV
Study NCT01817699 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: cholecalciferol
Description: 1,000 IU (1 tablet)/day, orally. Tablets are repacked into blister package.
Study NCT01798004 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: Given IV
Study NCT01798004 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: External Beam Radiation Therapy
Description: Undergo EBRT
Study NCT01817699 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: cholecalciferol
Description: 1,000 IU (1 tablet)/day, orally. Tablets are repacked into blister package.
Study NCT01713283 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SOF
Description: Sofosbuvir (SOF) 400 mg tablet administered orally once daily
Study NCT01713283 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RBV
Description: Ribavirin (RBV) tablets administered orally in a divided daily dose according to package insert weight-based dosing recommendations (\< 75kg = 1000 mg and ≥ 75 kg = 1200 mg)
Study NCT03262350 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Yoga
Description: The yoga classes will be adapted to all levels of experience, mobility, and body size. Specific breathing techniques and body positive language will be incorporated into a body-positive yoga training done by Ms. Lisa Diers, RDN, E-RYT, YACEP. Less focus will be placed on precision of the poses, instead focus will be on body feelings, except where physically dangerous. Thus, the overall focus will be on listening to one's own body. List of messages will be carefully designed to be related to eating and weight, but to not be directly discussed. Ms. Diers will travel to Delaware to lead the intervention training for yoga instructors prior to the study taking place.
Study NCT02626234 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INC280
Study NCT02626234 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: digoxin
Study NCT02626234 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rosuvastatin
Study NCT02690428 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Immunostimulating Interstitial Laser Thermotherapy
Description: Immunostimulating Interstitial Laser Thermotherapy (imILT) is a specific form of thermotherapy, which, in addition to destroying tumor tissue, has been optimized to cause a tumor specific immunologic response.
Study NCT03993990 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: individual empowerment-based intervention
Description: Participants will receive an empowerment-based intervention individually, based on five steps (i. e. problem identification, meaning and perception clarification, intervention planning, intervention delivery, and evaluation). After the principal investigator delivers a pre-discharge assessment (i. e. the self-care behavior and self-efficacy of diabetes and diabetic foot ulcer, risk factors of foot ulcer, family support, and threat belief of participant), the plan of behavioral modification will be determined by the principal investigator and participants. The subsequent follow-up and intensifying interventions will be delivered at the following time points: three days after discharge, every weeks for one month, every two weeks for subsequent two months, and then every three months for three times.
Study NCT00585221 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Peginterferon-alpha 2b (PegIFNa2b);
Description: Treatment include PegIFNa2b high dose (3 mcg/kg/wk) X 4 doses and low dose (1.5 mcg/kg/wk) X 18 doses, followed by surgical evaluation to render pt disease free if possible.
Study NCT01798004 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Filgrastim
Description: Given SC or IV
Study NCT01798004 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Optional correlative studies
Study NCT01798004 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melphalan
Description: Given IV
Study NCT01798004 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mesna
Description: Given IV
Study NCT01798004 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Peripheral Blood Stem Cell Transplantation
Description: Undergo autologous peripheral blood stem cell transplant
Study NCT01798004 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacological Study
Description: Correlative studies
Study NCT01798004 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Topotecan Hydrochloride
Description: Given IV
Study NCT01798004 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine Sulfate
Description: Given IV
Study NCT02329730 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 1μg/ml ESAT6-CFP10 and tuberculin purified protein derivative
Description: Left arm intradermal injection of 0.1ml TB-PPD(50IU/ml) by a syringe(1ml).Observe 30 minutes , if without obvious adverse reaction then right arm intradermal injection 1μg/ml ESAT6-CFP10 by a syringe(1ml). Inject ESAT6-CFP10 Allergen and TB-PPD only one time in the healthy subjects and the first part of tuberculosis subjects respectively.
Study NCT00585221 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Imatinib
Description: Continue imatinib until progression.
Study NCT02509052 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT02509052 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leflunomide
Description: Given PO
Study NCT02509052 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacological Study
Description: Correlative studies
Study NCT02329730 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 5μg/ml ESAT6-CFP10 and tuberculin purified protein derivative
Description: Left arm intradermal injection of 0.1ml TB-PPD(50IU/ml) by a syringe(1ml).Observe 30 minutes , if without obvious adverse reaction then right arm intradermal injection 5g/ml ESAT6-CFP10 by a syringe(1ml). Inject ESAT6-CFP10 Allergen and TB-PPD only one time in the healthy subjects and the first part of tuberculosis subjects respectively.
Study NCT01236911 — intervention group
Intervention type: OTHER
Intervention: Calcium Measurement
Description: after moderate-severe TBI (less as 24 hrs)
Study NCT03656588 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: a. Standard iodine scrub, 3% hydrogen peroxide prep, follow by ChloraPrep (2% chlorhexidine gluconate and 70% isopropyl alcohol
Description: a. Standard iodine scrub, 3% hydrogen peroxide prep, follow by ChloraPrep (2% chlorhexidine gluconate and 70% isopropyl alcohol
Study NCT03656588 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Iodine scrub and ChloraPrep alone
Description: Iodine scrub and ChloraPrep alone
Study NCT02354794 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: One form of arginine
Description: 3 capsules containing 0.5g of one form of L-arginine (1.5g) 3 times daily (4.5g per day) for 1 month
Study NCT02354794 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: placebo
Description: 3 capsules containing 0.5g cellulose (non active product) 3 times daily (4.5g per day) for 1 month
Study NCT02329730 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 10μg/ml ESAT6-CFP10 and tuberculin purified protein derivative
Description: Left arm intradermal injection of 0.1ml TB-PPD(50IU/ml) by a syringe(1ml).Observe 30 minutes , if without obvious adverse reaction then right arm intradermal injection 10g/ml ESAT6-CFP10 by a syringe(1ml). Inject ESAT6-CFP10 Allergen and TB-PPD only one time in the healthy subjects and the first part of tuberculosis subjects respectively.
Study NCT02329730 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 20μg/ml ESAT6-CFP10 and tuberculin purified protein derivative
Description: Left arm intradermal injection of 0.1ml TB-PPD(50IU/ml) by a syringe(1ml).Observe 30 minutes , if without obvious adverse reaction then right arm intradermal injection 20/ml ESAT6-CFP10 by a syringe(1ml). Inject ESAT6-CFP10 Allergen and TB-PPD only one time in the healthy subjects and the first part of tuberculosis subjects respectively.
Study NCT02329730 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 1μg/ml ESAT6-CFP10 and placebo
Description: Left arm intradermal injection of the placebo of 1μg/ml ESAT6-CFP10 by a syringe(1ml).Observe 30 minutes , if without obvious adverse reaction then right arm intradermal injection 1μg/ml ESAT6-CFP10 by a syringe(1ml). Inject ESAT6-CFP10 and placebo only one time in the second part of tuberculosis subjects.
Study NCT02329730 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 5μg/ml ESAT6-CFP10 and placebo
Description: Left arm intradermal injection of the placebo of 5μg/ml ESAT6-CFP10 by a syringe(1ml).Observe 30 minutes , if without obvious adverse reaction then right arm intradermal injection 5μg/ml ESAT6-CFP10 by a syringe(1ml). Inject ESAT6-CFP10 and placebo only one time in the second part of tuberculosis subjects.
Study NCT02329730 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 10μg/ml ESAT6-CFP10 and placebo
Description: Left arm intradermal injection of the placebo of 10μg/ml ESAT6-CFP10 by a syringe(1ml).Observe 30 minutes , if without obvious adverse reaction then right arm intradermal injection 10μg/ml ESAT6-CFP10 by a syringe(1ml). Inject ESAT6-CFP10 and placebo only one time in the second part of tuberculosis subjects.
Study NCT02329730 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 20μg/ml ESAT6-CFP10 and placebo
Description: Left arm intradermal injection of the placebo of 20μg/ml ESAT6-CFP10 by a syringe(1ml).Observe 30 minutes , if without obvious adverse reaction then right arm intradermal injection 20μg/ml ESAT6-CFP10 by a syringe(1ml). Inject ESAT6-CFP10 and placebo only one time in the second part of tuberculosis subjects.
Study NCT02342327 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: switch to non-menthol cigarettes prior to cessation attempt
Study NCT02342327 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: continue smoking menthol cigarettes prior to cessation attempt
Study NCT02113605 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cognitive behavior therapy
Description: Exposure-based cognitive behavior therapy in a 10 week face-to-face treatment
Study NCT04016753 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986256
Description: 30 mg(6ml)
Study NCT04016753 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Loestrin
Description: 1.5 mg Norethindrone and 30ug ethinyl estradiol
Study NCT00968994 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: The exSALT™ SD7 Wound Dressing
Description: The exSALT™ SD7 Wound Dressing is indicated for the management of partial and full thickness wounds, including decubitus ulcers, venous stasis ulcers, diabetic ulcers, first and second degree burns, grafts and donor sites, or other acute or chronic wounds. The dressing may be used over debrided and grafted wounds.
Study NCT00968994 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Xeroform® Petrolatum Dressing
Description: Sterile, single use, non-adherent dressing consisting of absorbent gauze impregnated with Xeroform in a petrolatum blend.
Study NCT01533389 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Silodosin
Description: Drug: silodosin dosage form : capsule dosage : placebo 4mg\*2 (8mg) frequency and duration : QD, 4weeks~Arms: Placebo
Study NCT01533389 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: dosage form : capsule dosage : placebo 4mg\*2 (8mg) frequency and duration : QD, 4weeks
Study NCT00995826 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CS-8958
Description: Inhaled CS-8958
Study NCT00995826 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Inhaled placebo
Study NCT01539694 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: LD118033 contact lens
Description: Multifocal contact lens worn on a daily wear basis for 1 week
Study NCT01539694 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: PureVision multifocal contact lens
Description: PureVision multifocal contact lens worn on a daily wear basis for 1 week.
Study NCT01119612 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Iron
Description: Daily oral dose of 60 mg from enrollment until delivery
Study NCT01119612 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Daily oral dose from enrollment until delivery
Study NCT02385045 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: i-scan
Description: i-scan function is located on the head of the Pentax endoscopes
Study NCT02385045 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: narrow band imaging
Description: narrow band imaging function is located on the head of Olympus endoscopes
Study NCT02297477 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: atovaquone-proguanil
Description: A daily fixed dose combination of 4 tablets containing atovaquone 250mg and proguanil hydrochloride 100mg (total 1000mg/400mg respectively)
Study NCT02297477 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: artesunate-atovaquone-proguanil
Description: A daily fixed dose combination of 4 tablets containing atovaquone 250mg and proguanil hydrochloride 100mg (total 1000mg/400mg daily respectively) in addition to 4 tablets containing 50mg artesunate (200mg daily)
Study NCT01793649 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GS-5737
Description: A single dose of GS-5737 in 2.8% saline
Study NCT02894918 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Peginterferon alfa-2a
Description: 180ug/0.5ml,hypodermic injection once a week